Search details
1.
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
N Engl J Med
; 386(5): 449-462, 2022 02 03.
Article
in English
| MEDLINE | ID: mdl-35108470
2.
Anti-integrin αvß6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis.
Br J Cancer
; 130(9): 1552-1560, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38461170
3.
Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).
Oncologist
; 29(3): e330-e336, 2024 Mar 04.
Article
in English
| MEDLINE | ID: mdl-37950903
4.
New therapeutic target molecules for gastric and gastroesophageal junction cancer.
Int J Clin Oncol
; 2024 Apr 17.
Article
in English
| MEDLINE | ID: mdl-38630383
5.
Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902).
Int J Clin Oncol
; 29(2): 134-141, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38227090
6.
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Br J Cancer
; 128(10): 1897-1905, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36871043
7.
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).
Br J Cancer
; 129(6): 1032-1039, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37532830
8.
The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results.
Oncologist
; 28(7): e565-e574, 2023 07 05.
Article
in English
| MEDLINE | ID: mdl-35947993
9.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
N Engl J Med
; 382(25): 2419-2430, 2020 06 18.
Article
in English
| MEDLINE | ID: mdl-32469182
10.
Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study.
Invest New Drugs
; 41(1): 1-12, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36331674
11.
Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
BMC Cancer
; 23(1): 726, 2023 Aug 05.
Article
in English
| MEDLINE | ID: mdl-37543568
12.
Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials.
Gastric Cancer
; 26(5): 788-797, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37335367
13.
Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106).
Int J Clin Oncol
; 28(9): 1176-1182, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37418143
14.
Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer.
Int J Clin Oncol
; 28(11): 1501-1510, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37634209
15.
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Esophagus
; 20(2): 281-289, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36484900
16.
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Esophagus
; 20(2): 291-301, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36401133
17.
Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.
Cancer Sci
; 113(8): 2814-2827, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35701865
18.
Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).
Oncologist
; 27(4): 251-e304, 2022 04 05.
Article
in English
| MEDLINE | ID: mdl-35380725
19.
Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S - 1 therapy.
BMC Cancer
; 22(1): 773, 2022 Jul 15.
Article
in English
| MEDLINE | ID: mdl-35840917
20.
Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
BMC Cancer
; 22(1): 811, 2022 Jul 23.
Article
in English
| MEDLINE | ID: mdl-35870893